ClinicalTrials.gg
RecruitingNCT07700979G/GEJUpdated Sep 29, 2026

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

A Phase 3 interventional study of Cadonilimab and CAPOX regimen in Gastric / Gastroesophageal Junction Adenocarcinoma, sponsored by Akeso. Recruiting at 25 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Akeso · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Sep 29, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing cadonilimab in Stomach Neoplasms — 10 open to participants now, 11 under way, 3 of them phase 3. cadonilimab · Stomach Neoplasms.

Planned enrollment
Largest of 12
900 · median 39
Started
2026
with 1 other
Phase 3
2 of 12
2 open now
Primary completion
2029-08
later than 10 of 10 live
Registered
12th of 12
by date
Lead sponsor
1 of 12
Akeso

Among the 12 studies testing cadonilimab in Stomach Neoplasms, this one has the largest planned enrollment, is one of 2 that started in 2026, is one of 2 in phase 3, reaches primary completion later than 10 of the 10 other live ones, and was the 12th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

10 of the 12 studies testing cadonilimab in Stomach Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

About cadonilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing cadonilimab in Stomach Neoplasms, or all of them as a file.
02

Study summary

The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma trial is to compare OS between cadonilimab combined with chemotherapy and chemotherapy in combination with or without nivolumab in the ITT population.

03

Conditions studied

  • Gastric / Gastroesophageal Junction Adenocarcinoma

Browse trials for

Keywords

  • Gastric/GEJ adenocarcinoma
  • gastric cancer
  • cadonilimab
  • nivolumab
  • chemotherapy
  • HER2-negative cancer
  • Immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide written and can understand and comply with the requirements of the study.
  2. Histopathologically-confirmed diagnosis of locally advanced unresectable or G/GEJ adenocarcinoma.
  3. No prior systemic therapy for locally advanced unresectable or metastatic G/GEJ adenocarcinoma. NOTE: For participants who have received prior /adjuvant therapy for curative intent, the time between disease progression and last treatment should be at least 6 months.
  4. PS of 0 or 1 within 3 days prior to randomization.
  5. Age ≥ 18 years at the time of voluntarily signing informed consent.
  6. Evaluable expression results.
  7. Participants must have at least one per v1.1 as assessed by investigator assessment. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  8. Adequate organ function as indicated by the following laboratory values. Specimens must be collected within 7 days prior to the first dose of study treatment.
  9. ≥3 months.
  10. Women of (WOCBP) must have a negative serum pregnancy test within 7 days prior to the first dose and agree to use effective during treatment, and for at least 150 days after the last dose of cadonilimab/nivolumab, 270 days after the last dose of oxaliplatin, and 180 days after the last dose of capecitabine.
  11. Non-sterile males must agree to use effective contraception during treatment and for at least 120 days following the last dose of cadonilimab/nivolumab/capecitabine and 180 days after the last dose of oxaliplatin.

Exclusion criteria

Exclusion Criteria:

  1. Histopathologically confirmed other pathological types, such as squamous cell carcinoma, sarcoma or undifferentiated carcinoma.
  2. Known positive. Be HER2-positive defined as either IHC 3+ or IHC 2+ in combination with ISH+ (or FISH).
  3. Participants with active central nervous system (CNS) and/or carcinomatous meningitis. Participants with previously treated may participate provided they are radiologically stable (i.e., without evidence of progression) for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of treatment for at least 14 days prior to first dose of study intervention.
  4. Presence of clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring frequent drainage (≥ 1 time/month).
  5. bleeding symptoms within 28 days before the first dose or a definite tendency to bleed.
  6. Have a history of ≥ Grade 2 gastrointestinal perforation and/or fistulae (including prior gastric fistula operation) within 6 months prior to randomization.
  7. Participants who, in the opinion of the investigator, have symptoms or signs suggestive of clinically unacceptable deterioration of the primary disease at the time of screening.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
900 participants (estimated)

Study arms

  • Experimental
    Cadonilimab/placebo+CAPOX

    Cadonilimab/placebo in combination with oxaliplatin and capecitabine (CAPOX)

    Drug: Cadonilimab · Drug: CAPOX regimen · Drug: Placebo

  • Active comparator
    CAPOX±nivolumab/placebo

    Oxaliplatin and capecitabine with or without nivolumab (CAPOX)

    Drug: CAPOX regimen · Drug: Nivolumab · Drug: Placebo

Interventions

  • Anti-PD-1/ CTLA-4 tetrameric bispecific antibody

  • DrugCAPOX regimen

    A combination treatment contains oxaliplatin and capecitabine

  • Anti-PD-1 monoclonal antibody

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    Time from randomization to death from any cause

    Time frame: Approximately up to 14months

Secondary outcomes

  1. Progression-free survival(PFS)

    Time from the date of randomization to the date of progressive disease or death from any cause, whichever occurs first.

    Time frame: Approximately up to 8 months

  2. Objective response rate (ORR)

    Time frame: Approximately up to 8 months

  3. Disease control rate (DCR)

    Time frame: Approximately up to 8 months

  4. Duration of response (DoR)

    Time frame: Approximately up to 8 months

  5. Safety assessment

    Incidence and severity of adverse events (AEs) and clinically significant abnormal laboratory test results

    Time frame: Approximately up to 18 months

07

Study locations

1 of 25 sites recruiting
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
    Not yet recruiting
    • Ashish Chintakuntlawar, · Contact
  • UCLA Health
    Los Angeles, California 90095, United States
    Not yet recruiting
    • Randy Hecht, MD · Contact
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
    Not yet recruiting
    • Allen L Cohn, MD · Contact
  • Yale School of Medicine
    New Haven, Connecticut 06510, United States
    Not yet recruiting
    • Raghav Sundar, MD · Contact
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Not yet recruiting
  • Henry Ford Health
    Detroit, Michigan 48202, United States
    Not yet recruiting
    • Zaid AI-Saheli, MD · Contact
  • Mount Sinai
    New York, New York 10029, United States
    Not yet recruiting
    • Deirdre Cohen, MD · Contact
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Not yet recruiting
    • Yelena Janjigian, MD · Contact
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
    Not yet recruiting
    • Emerson Chen, MD · Contact
  • Sarah Cannon Research Institute (SCRI) - Oncology Partners
    Nashville, Tennessee 37203, United States
    Not yet recruiting
    • David R Spigel, MD · Contact
  • Baylor Scott & White Health
    Dallas, Texas 75246, United States
    Not yet recruiting
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Not yet recruiting
    • Jaffer A. Ajani,, MD · Contact
  • University of Wisconsin Carbone Cancer Center
    Madison, Wisconsin 53792, United States
    Not yet recruiting
    • Nataliya Uboha, MD · Contact
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, China
    Not yet recruiting
    • Wei Deng, MD · Contact
  • Peking University Cancer Hospital, Gastrointestinal Cancer Center I
    Beijing, China
    Recruiting
    • Jiafu Ji, MD · Contact
  • Peking University Cancer Hospital, Gastrointestinal Oncology
    Beijing, China
    Not yet recruiting
    • Lin Shen, MD · Contact
  • Guangdong Provincial People's Hospital
    Guangzhou, China
    Not yet recruiting
    • Jian Xiao, MD · Contact
  • Zhongshan Hospital Fudan University
    Shanghai, China
    Not yet recruiting
    • Xuefei Wang, MD · Contact
  • Universitaetsklinikum Essen
    Essen, North Rhine-Westphalia, Germany
    Not yet recruiting
    • Isabel Virchow, MD · Contact
  • University Cancer Center Frankfurt
    Frankfurt, Germany
    Not yet recruiting
    • Thorsten O Goetze, MD · Contact
  • Universitätsmedizin der Johannes Gutenberg-Universität
    Mainz, Germany
    Not yet recruiting
    • Markus Mohler, MD · Contact
  • Univerity Marburg
    Marburg, Germany
    Not yet recruiting
  • Pratia MCM Kraków
    Krakow, Poland
    Not yet recruiting
  • Pratia Poznań
    Poznan, Poland
    Not yet recruiting
    • Piotr Tomczak, MD · Contact
  • Narodowy Instytut Onkologii-im. Marii Sklodowskiej Curie Panstwowy Instytut Badawczy - w Warszawie
    Warsaw, Poland
    Not yet recruiting
    • Lucjan S Wyrwicz, MD · Contact
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2029, 34 months after the start.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's planned 34 months is below that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 14, 2026
StartActual
Sep 24, 2026was Aug 2026
Primary completionEst.
Aug 18, 2029
CompletionEst.
Aug 18, 2030
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 29, 2026
Sites
25 sites changed recruiting status (24 now not yet recruiting, 1 now recruiting)
Show 25 sites
  • Mayo Clinic · Phoenix, United Statesno status→Not yet recruiting
  • UCLA Health · Los Angeles, United Statesno status→Not yet recruiting
  • Rocky Mountain Cancer Centers · Denver, United Statesno status→Not yet recruiting
  • Yale School of Medicine · New Haven, United Statesno status→Not yet recruiting
  • Dana Farber Cancer Institute · Boston, United Statesno status→Not yet recruiting
  • Henry Ford Health · Detroit, United Statesno status→Not yet recruiting
  • Mount Sinai · New York, United Statesno status→Not yet recruiting
  • Memorial Sloan Kettering Cancer Center · New York, United Statesno status→Not yet recruiting
  • Oregon Health and Science University · Portland, United Statesno status→Not yet recruiting
  • Sarah Cannon Research Institute (SCRI) - Oncology Partners · Nashville, United Statesno status→Not yet recruiting
  • Baylor Scott & White Health · Dallas, United Statesno status→Not yet recruiting
  • MD Anderson Cancer Center · Houston, United Statesno status→Not yet recruiting
  • University of Wisconsin Carbone Cancer Center · Madison, United Statesno status→Not yet recruiting
  • Beijing Friendship Hospital, Capital Medical University · Beijing, Chinano status→Not yet recruiting
  • Peking University Cancer Hospital, Gastrointestinal Cancer Center I · Beijing, Chinano status→Recruiting
  • Peking University Cancer Hospital, Gastrointestinal Oncology · Beijing, Chinano status→Not yet recruiting
  • Guangdong Provincial People's Hospital · Guangzhou, Chinano status→Not yet recruiting
  • Zhongshan Hospital Fudan University · Shanghai, Chinano status→Not yet recruiting
  • Universitaetsklinikum Essen · Essen, Germanyno status→Not yet recruiting
  • University Cancer Center Frankfurt · Frankfurt, Germanyno status→Not yet recruiting
  • Universitätsmedizin der Johannes Gutenberg-Universität · Mainz, Germanyno status→Not yet recruiting
  • Univerity Marburg · Marburg, Germanyno status→Not yet recruiting
  • Pratia MCM Kraków · Krakow, Polandno status→Not yet recruiting
  • Pratia Poznań · Poznan, Polandno status→Not yet recruiting
  • Narodowy Instytut Onkologii-im. Marii Sklodowskiej Curie Panstwowy Instytut Badawczy - w Warszawie · Warsaw, Polandno status→Not yet recruiting
Sep 29, 2026
Start date
Aug 20, 2026→Sep 24, 2026 (actual)
Sep 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Memorial Sloan Kettering Cancer Center · New York, United StatesContact added (no phone or email listed)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Not yet recruiting→Recruiting
    25 sites changed recruiting status (24 now not yet recruiting, 1 now recruiting)
    Show 25 sites
    • Mayo Clinic · Phoenix, United Statesno status→Not yet recruiting
    • UCLA Health · Los Angeles, United Statesno status→Not yet recruiting
    • Rocky Mountain Cancer Centers · Denver, United Statesno status→Not yet recruiting
    • Yale School of Medicine · New Haven, United Statesno status→Not yet recruiting
    • Dana Farber Cancer Institute · Boston, United Statesno status→Not yet recruiting
    • Henry Ford Health · Detroit, United Statesno status→Not yet recruiting
    • Mount Sinai · New York, United Statesno status→Not yet recruiting
    • Memorial Sloan Kettering Cancer Center · New York, United Statesno status→Not yet recruiting
    • Oregon Health and Science University · Portland, United Statesno status→Not yet recruiting
    • Sarah Cannon Research Institute (SCRI) - Oncology Partners · Nashville, United Statesno status→Not yet recruiting
    • Baylor Scott & White Health · Dallas, United Statesno status→Not yet recruiting
    • MD Anderson Cancer Center · Houston, United Statesno status→Not yet recruiting
    • University of Wisconsin Carbone Cancer Center · Madison, United Statesno status→Not yet recruiting
    • Beijing Friendship Hospital, Capital Medical University · Beijing, Chinano status→Not yet recruiting
    • Peking University Cancer Hospital, Gastrointestinal Cancer Center I · Beijing, Chinano status→Recruiting
    • Peking University Cancer Hospital, Gastrointestinal Oncology · Beijing, Chinano status→Not yet recruiting
    • Guangdong Provincial People's Hospital · Guangzhou, Chinano status→Not yet recruiting
    • Zhongshan Hospital Fudan University · Shanghai, Chinano status→Not yet recruiting
    • Universitaetsklinikum Essen · Essen, Germanyno status→Not yet recruiting
    • University Cancer Center Frankfurt · Frankfurt, Germanyno status→Not yet recruiting
    • Universitätsmedizin der Johannes Gutenberg-Universität · Mainz, Germanyno status→Not yet recruiting
    • Univerity Marburg · Marburg, Germanyno status→Not yet recruiting
    • Pratia MCM Kraków · Krakow, Polandno status→Not yet recruiting
    • Pratia Poznań · Poznan, Polandno status→Not yet recruiting
    • Narodowy Instytut Onkologii-im. Marii Sklodowskiej Curie Panstwowy Instytut Badawczy - w Warszawie · Warsaw, Polandno status→Not yet recruiting
    Start date Aug 20, 2026→Sep 24, 2026 (now actual)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Memorial Sloan Kettering Cancer Center · New York, United StatesContact added (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07700979
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Sep 24, 2026
Primary completion
Aug 18, 2029 (estimated)
Completion
Aug 18, 2030 (estimated)
Last update
Sep 29, 2026

Study contacts

Zhifang Yao, MD
Contact
clinicaltrials@akesobio.com
86-0760-89873999
Yelena Janjigian, MD
Contact
Jiafu Ji, MD
principal investigator · Peking University Cancer Hospital, Beijing, Beijing 100142, China
Lin Shen, MD
principal investigator · Peking University Cancer Hospital, Beijing, Beijing 100142, China
Markus Mohler, MD
principal investigator · Johannes Gutenberg University Clinic, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cadonilimab

Start the discussion